Abstracts tagged "pregnancy and rheumatic disease"

Abstract Number: 1249 • 2018 ACR/ARHP Annual Meeting
Contraception Compliance in Patients with Rheumatological Diseases on Disease Modifying Antirheumatic and Cytotoxic Drugs
Sara Naji Rad¹, Paris Pacheco², Luis Calvo², Htet Htet Maung², Wajiha Illyas² and Prachi Anand³, ¹Internal Medicine, Nassau University Medical Center, East meadow, NY, ²Internal Medicine, Nassau University Medical Center, East Meadow, NY, ³Chief of Rheumatology, Nassau University Medical Center, East Meadow, NY
Background/Purpose: Women of child bearing age with autoimmune diseases are often prescribed teratogenic medications as Methotrexate, Mycophenolate Mofetil, Leflunomide and Cyclophosphamide. Contraceptive compliance in this…
Abstract Number: 2419 • 2018 ACR/ARHP Annual Meeting
Needs Assessment and Implementation of a Reproductive Health Intention Screen for Women with Systemic Rheumatic Diseases
Elizabeth Janiak¹, Latoya Bartlett², Joy Gulla², Bill Albert³, Sonali Desai⁴, Susan Ritter⁵, Laura Tarter⁵, Jonathan Coblyn⁵, Bonnie L. Bermas⁶, Wan-Ju Wu¹, Caryn Dutton¹, Lydia Pace⁷ and Candace H. Feldman⁴, ¹Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Power to Decide, Washington, DC, DC, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶Rheumatology, University of Texas, Southwestern, Dallas, TX, ⁷Division of Women's Health, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Among women with systemic rheumatic diseases (SRD), poor maternal and fetal outcomes may occur if disease activity and medication use are not optimized preconception.…
Abstract Number: 1301 • 2017 ACR/ARHP Annual Meeting
Congenital Heart Defects in Children Born to Mothers with Rheumatic Disease and Anti-Ro and/or Anti-La Antibodies
Julie Couture¹, Linda T Hiraki², Franklin Silverio¹, Deepika Sharma¹ and Earl Silverman³, ¹Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, ²Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ³Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Transplacental passage of maternal anti-Ro IgG is thought to be critical in initiating inflammation leading to congenital heart block in neonatal lupus erythematosus (NLE).…
Abstract Number: 1303 • 2017 ACR/ARHP Annual Meeting
Polycystic Ovarian Syndrome in Rheumatic Disease
Cuoghi Edens¹ and Maria Antonelli², ¹Division of Pediatric Infectious Diseases and Rheumatology and Division of Rheumatology, Rainbow Babies and Children's Hospital and University Hospitals Cleveland Medical Center, Cleveland, OH, ²Department of Medicine/Division of Rheumatology, Case Western Reserve University School of Medicine, MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Polycystic ovarian syndrome (PCOS) is a common entity in the general population associated with polycystic ovaries, oligomenorrhea, difficulty conceiving, hormone abnormalities, metabolic comorbidities, and…
Abstract Number: 1809 • 2017 ACR/ARHP Annual Meeting
Lack of Placental Transfer of Certolizumab Pegol during Pregnancy: Results from a Prospective, Postmarketing, Multicenter, Pharmacokinetic Study
Eliza Chakravarty¹, Frauke Förger², Bincy Abraham³, Ann Flynn⁴, Anna Moltó⁵, René-Marc Flipo⁶, Astrid van Tubergen⁷, Laura Shaughnessy⁸, Jeff Simpson⁸, Marie Teil⁹, Eric Helmer¹⁰, Maggie Wang⁸ and Xavier Mariette¹¹, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Department of Rheumatology and Clinical Immunology and Allergology, Inselspital, University of Bern, Bern, Switzerland, ³Houston Methodist Hospital, Houston, TX, ⁴University of Utah, Salt Lake City, UT, ⁵Hôpital Cochin, AP-HP, Paris, France, ⁶Centre Hospitalier Régional Universitaire de Lille, Lille, France, ⁷Maastricht University Medical Center, Maastricht, Netherlands, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹INSERM U1184, Université Paris-Sud, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France
Background/Purpose: There is a need for effective and safe treatment during pregnancy in women affected by chronic active inflammatory diseases such as rheumatoid arthritis. Adequate…
Abstract Number: 1958 • 2017 ACR/ARHP Annual Meeting
Burden of Rheumatic Disease Among Korean Women in Childbearing Years Based on the National Health Insurance Service-National Sample Cohort
Min Kyung Chung¹, Jisoo Lee¹, Eun-Hee Ha² and Ji-Young Shin², ¹Division of Rheumatology, Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea, Republic of (South), ²Department of Occupational and Environmental Medicine, Ewha Womans University School of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Many rheumatic diseases predominantly affect women in their reproductive years, and have a significant impact on childbearing, but its burden remains incompletely understood. The…
Abstract Number: 2435 • 2016 ACR/ARHP Annual Meeting
Counseling on Family Planning and Contraception, and Pregnancy Outcome in Women with Rheumatic Diseases: Analysis of 398 Patient-Reported Questionnaires from a Multicenter Italian Study
Francesca Dall'Ara¹, Maria Grazia Lazzaroni¹, Laura Andreoli¹, Marilia Rodrigues², Carolina Benigno³, Elena Bartoloni-Bocci⁴, Corrado Capochiaro⁵, Cecilia B. Chighizola⁶, Paola Conigliaro⁷, ADA Corrado⁸, Salvatore D'Angelo⁹, maria favaro¹⁰, Elena Generali¹¹, Maria Gerosa¹², M larosa¹³, Marianna Meroni¹⁴, Melissa Padovan¹⁵, Giulia Pazzola¹⁶, Susanna Peccatori¹⁷, Imma Prevete¹⁸, Véronique Ramoni¹⁹, G Sebastiani²⁰, Chiara Tani²¹, Marica Trevisani²², M Vadacca²³, Ester Vivaldelli²⁴, E Visalli²⁵, L Zuliani²⁶, A Afeltra²³, Elena Baldissera²⁷, Antonio Brucato²⁸, Francesco Paolo Cantore²⁹, Roberto Caporali³⁰, Maurizio Cutolo³¹, Andrea Doria³², Rosario Foti³³, Armando Gabrielli³⁴, Roberto Gerli³⁵, Marcello Govoni³⁶, Armin Maier²⁴, Nazzarena Malavolta³⁷, Pier Luigi Meroni³⁸, Giovanni Minisola¹⁸, Carlo Maurizio Montecucco³⁹, Marta Mosca⁴⁰, Ignazio Olivieri⁴¹, Giuseppe Paolazzi⁴², Roberto Perricone⁴³, N Romeo⁴⁴, Amelia Ruffatti⁴⁵, Maria Grazia Sabbadini⁵, Carlo Salvarani⁴⁶, Carlo Selmi⁴⁷, Luigi Sinigaglia⁴⁸ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, Coimbra, Portugal, ³University Federico II, Napoli, Italy, Napoli, Jamaica, ⁴Department of Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ⁵Ospedale San Raffaele, Milano, Italy, milano, Italy, ⁶Department of Clinical Sciences and Community Health, University of Milan, IRCCS Istituto Auxologico Italiano, Milano, Italy, ⁷Policlinico and University of Tor Vergata, Roma, Italy, roma, Italy, ⁸Ospedali Riuniti of Foggia, Foggia, Italy, foggia, Italy, ⁹Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, matera, Italy, ¹⁰Rheumatology Unit, University and Azienda Ospedaliera of Padova, Padova, Italy, padova, Italy, ¹¹Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano (MI), Italy, ¹²University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy, ¹³University and Azienda Ospedaliera of Padova, Padova, Italy, padova, Italy, ¹⁴University of Genova-IRCCS San Martino Genova, Genova, Italy and ASST Papa Giovanni XXIII, Bergamo, Italy, genova, Italy, ¹⁵Department if Clinical and Experimental Medicine, University of Ferrara, Section of Rheumatology, Ferrara, Italy, ¹⁶Rheumatology Unit, Internal Medicine Department, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, ¹⁷Azienda Provinciale Servizi Sanitari, Trento, Italy, trento, Italy, ¹⁸Azienda Ospedaliera San Camillo, Roma, Italy, Roma, Italy, ¹⁹Rheumatology, Policlinico San Matteo, Pavia, Italy, ²⁰15 Azienda Ospedaliera San Camillo, Roma, Italy, roma, Italy, ²¹Clinical and Experimental Medicine, University of Pisa, Rheumatology Unit, Pisa, Italy, ²²Rheumatology Unit, Internal Medicine, Policlinico S.Orsola-Malpighi, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, ²³University Campus Biomedico, Roma, Italy, roma, Italy, ²⁴Ospedale of Bolzano, Bolzano, Italy, bolzano, Italy, ²⁵A.O.U. Policlinico Vittorio Emanuele, Catania, Italy, catania, Italy, ²⁶Ospedali Riuniti and University of Ancona, Ancona, Italy, ancona, Italy, ²⁷Internal Medicine and Clinical Immunology, Vita-Salute San Raffaele University, Milan, Italy, ²⁸Internal Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy, ²⁹Ospedali Riuniti of Foggia, Foggia, Italy, Foggia, Italy, ³⁰Università di Pavia, Pavia, Italy, ³¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genova, Italy, ³²Rheumatology Unit, Department of Medicine - DIMED, Department of Medicine-DIMED, University of Padova, Padova, Italy, ³³Rheumatology Unit, Vittorio-Emanuele University Hospital of Catania, Catania, Italy, ³⁴Medical Clinic Unit, Department of Internal Medicine, Ospedali Riuniti, Ancona, Italy, ³⁵Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Italy, Perugia, Italy, ³⁶Department of Clinical and Experimental Medicine, Rheumatology Unit-Azienda Ospedaliera-Universitaria Sant'Anna, Ferrara, Italy, ³⁷Internal medicine Unit, Policlinico S. Orsola Malpighi, Bologna, Italy, ³⁸Rheumatology Department, University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy, ³⁹Division of Rheumatology, University of Pavia School of Medicine, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ⁴⁰Rheumatology Unit, University of Pisa, Pisa, Italy, ⁴¹U.O. Reumatologia, A.O. Ospedale San Carlo, Potenza, Italy, ⁴²Rheumatology Unit, Santa Chiara Hospital, Trento, Italy, ⁴³Rheumatology, allergology and clinical immunology, University of Rome Tor Vergata, Rome, Italy, ⁴⁴Ospedale S.Croce e Carle, Cuneo, Italy, cuneo, Italy, ⁴⁵Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, ⁴⁶Rheumatology Unit, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ⁴⁷Internal Medicine- Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano, Italy, ⁴⁸University of Milan, Milan, Italy, milano, Italy
COUNSELING ON FAMILY PLANNING AND CONTRACEPTION, AND PREGNANCY OUTCOME IN WOMEN WITH RHEUMATIC DISEASES: ANALYSIS OF 398 PATIENT-REPORTED QUESTIONNAIRES FROM A MULTICENTER ITALIAN STUDYBackground/Purpose: Rheumatic…
Abstract Number: 2125 • 2015 ACR/ARHP Annual Meeting
Rheumatic and Non-Rheumatic Autoimmune Diseases in SLE Offspring
Julie Couture¹, Sasha Bernatsky², Susan Scott³, Christian A. Pineau² and Evelyne Vinet², ¹McGill University Health Centre, Montreal, QC, Canada, ²Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ³Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Autoimmune diseases (AID) have familial aggregation and frequently share a common genetic predisposition. Only few small uncontrolled studies have evaluated the risk of AID…
Abstract Number: 2523 • 2015 ACR/ARHP Annual Meeting
Characteristics and Outcomes of Prospectively-Reported Pregnancies Exposed to Certolizumab Pegol from a Safety Database
Megan E. B. Clowse¹, Douglas C. Wolf², Amanda Golembesky³, Laura Shaughnessy⁴, Dirk De Cuyper⁵ and Frauke Förger⁶, ¹Rheumatology & Immunology, Duke University, Durham, NC, ²Atlanta Gastroenterology Associates, Atlanta, GA, ³UCB Pharma, Raleigh, NC, ⁴8010 Arco Corporate Drive, Sui, UCB Pharma, Raleigh, NC, ⁵Safety Patient Solutions BioBrands, UCB Pharma, Brussels, Belgium, ⁶Rheumatology, Clinical Immunology and Allergology, Inselspital-University Hospital, Bern, Switzerland
Background/Purpose: Data on the impact of anti-TNF medications on pregnancy outcomes are limited. Certolizumab pegol (CZP) is a PEGylated Fc-free anti-TNF approved in more than…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].